Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07172919 · ClinicalTrials.gov registry record · Phase 2
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
A Phase 2 study of Advanced Solid Tumors, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 4
- Study locations
NCT07172919 is a Phase 2 study of Advanced Solid Tumors that is actively recruiting participants, run by Amgen. The registered enrollment target is 14 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT07172919, a Phase 2 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 4
- Study locations
Study Summary
The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.
Conditions Studied
Interventions
- DRUG Sotorasib
- DRUG Panitumumab
Study Locations (4)
Other
- Universitaetsspital Basel - Basel
- Taichung Veterans General Hospital - Taichung
Texas
- University of Texas MD Anderson Cancer Center - Houston
Hokkaido
- National Hospital Organization Hokkaido Cancer Center - Sapporo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2026-01-02 |
| Est. Completion | 2028-01-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07172919
The ClinicalTrials.gov registry entry for NCT07172919 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (93% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Sotorasib is the first listed.
NCT07172919 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, Texas, Hokkaido.
Frequently Asked Questions
What is clinical trial NCT07172919 about?
NCT07172919 is a clinical study titled "A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation". The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.
What is the current status of trial NCT07172919?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2026-01-02. Estimated completion is 2028-01-02.
What conditions does trial NCT07172919 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT07172919?
The interventions under investigation include: Sotorasib (DRUG), Panitumumab (DRUG).
Who is sponsoring clinical trial NCT07172919?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07172919 being conducted?
This trial has 4 study locations across Texas, Hokkaido. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
RECRUITING · Phase 2
-
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RECRUITING · Phase 2
-
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RECRUITING · Phase 2
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
COMPLETED · Phase 2
-
A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.